Polynucleotides, PRP and exosomes: evidence compared

Polynucleotides, platelet-rich plasma and exosome-related preparations are different intervention categories. Evidence for one does not establish the effects of another. Direct comparisons require clearly described treatments tested in the same human study, for the same indication and outcome. Separate studies can provide context, but cannot reliably show which approach performs better.

What this evidence comparison covers

This reference compares three categories that are sometimes placed together under regenerative or restorative language: polynucleotide preparations, platelet-rich plasma, usually called PRP, and exosome-related preparations. They should not be treated as interchangeable categories. Their composition, preparation and biological description differ, as do the questions a clinical study must answer.

Polynucleotide preparations contain chains of nucleotides, the building blocks of nucleic acids. PRP is produced from a sample of the recipient's blood and contains platelets suspended in plasma. Exosome-related preparations are generally discussed within the wider field of extracellular vesicles. The International Society for Extracellular Vesicles explains in its MISEV2018 guidance that researchers should describe extracellular-vesicle preparations according to the characterisation actually performed. This matters because a label alone does not establish the identity, purity or consistency of a preparation.

The focus here is human injectable-treatment evidence. Cell studies, laboratory assays and animal studies can be useful for exploring a possible mechanism. They do not, on their own, demonstrate a patient-relevant effect, establish an appropriate treatment protocol or compare one injectable category with another.

A direct comparison means that the same human study tests clearly identified approaches for the same clinical question. For example, a study of PRP against a control is not automatically a comparison with polynucleotides. Nor can a study in one condition answer a question about another condition, body area or outcome. The central task is to distinguish evidence that answers a comparison from evidence that merely sits alongside it.

Why the intervention must be defined first

The first question is not whether an intervention belongs to a broad category. It is what was actually injected. A study result applies most securely to the material, preparation process, delivery method, treatment schedule and population described in that study. Similar-sounding labels may conceal meaningful differences in one or more of those elements.

For PRP, relevant details can include how blood was collected, how the preparation was processed, the resulting platelet preparation and how it was administered. PRP is autologous, meaning it is derived from the person receiving it, but that fact does not make all PRP protocols identical. If studies use different preparation methods or injection schedules, their findings may not be directly transferable from one protocol to another.

For polynucleotides, the study should identify the material used and the treatment protocol. Terms such as polynucleotide and polydeoxyribonucleotide may appear in the literature, but terminology alone is not enough to show that two interventions are materially equivalent. The reader should look for a usable description of the preparation and its administration.

Exosome-related claims need especially careful wording. MISEV2018 advises use of terminology that reflects the extent to which extracellular vesicles have been characterised. A preparation described broadly as exosome-based may not have been shown to contain only exosomes. Therefore, a result reported for one extracellular-vesicle preparation cannot safely be extended to every preparation using exosome language.

These distinctions are not technical distractions. They determine whether a study answers the question being asked. When the intervention cannot be adequately identified, the appropriate conclusion is that its relevance to another preparation is uncertain.

Evidence comparison table

The table separates direct evidence from indirect evidence. Direct evidence requires a controlled human comparison of the named approaches for the same indication, with comparable outcome measurement. Indirect evidence may still be informative about an individual intervention, but it cannot establish that one category is superior, equivalent or more suitable than another.

Decision rule: do not use language of superiority or equivalence unless the same controlled human study compares sufficiently described interventions for the same indication and outcome. If those elements are missing, describe the relationship as indirect, uncertain or not established.

This rule does not mean that every uncontrolled study is without value. Such studies can identify questions for further research and record experiences within their own limits. The rule simply prevents a series of separate studies from being converted into a treatment ranking that none of them tested.

How to read outcomes and comparators

A reported outcome is only as useful as the question it measures. Participant-reported change, investigator assessment, standardised photography, instrumental measurements and tissue findings are different outcome domains. Improvement on one measure does not automatically demonstrate improvement on another. A study should specify what was measured, when it was measured and how the assessment was made.

Timing is part of comparability. An early assessment after one intervention cannot readily be placed against a later assessment after another. The same applies where one study examines a short-term procedural response while another reports a longer-term participant-reported outcome. Putting both findings in adjacent columns may look like a comparison, but it does not make the results like for like.

Comparator choice also changes what can be concluded. A controlled study may compare an intervention with no treatment, placebo, usual care or another active intervention. A before-and-after study records change over time in one group, but cannot reliably separate an intervention's contribution from natural variation, concurrent care, expectation or measurement effects. Random allocation can reduce certain sources of bias, but it does not cure poor intervention description or an unsuitable outcome.

Indication must remain fixed throughout the comparison. Hair loss, for example, is not a single diagnosis. Different causes, stages and patterns may have different clinical courses. A finding in one defined hair condition should not be generalised to every form of hair loss. The same principle applies to skin concerns and other proposed uses: evidence should be read at the level of the condition and outcome actually studied.

A meaningful head-to-head study therefore aligns four elements: a defined intervention, a defined population, a common comparator framework and a common outcome at a common time point.

A screenshot rule for comparison claims

Use this sequence when reading a statement that one injectable category is better than, safer than or equivalent to another. It applies to claims made in conversation, published material or clinical discussion. It is an evidence-reading rule, not an instruction to undertake or avoid treatment.

1. Identify the material. Does the source say what was injected, how it was prepared and how it was delivered? If not, the intervention is insufficiently specified.
2. Identify the indication. Were both approaches assessed for the same defined condition or concern? If not, the comparison is indirect.
3. Identify the study design. Did the same human study include both approaches, or are the claims drawn from separate publications? Separate publications cannot answer a head-to-head question reliably.
4. Match outcomes and follow-up. Were the same pre-specified measures assessed at the same time point? If not, an apparent difference may reflect measurement or timing rather than treatment effect.
5. Check the limits. Consider the size of the study, handling of missing data, completeness of reporting and whether the participants and protocol resemble the situation under discussion.

Screenshot rule: A comparison claim needs a controlled human study of clearly described interventions, for the same indication, using the same outcome at the same follow-up. Without that, it is not evidence that one injectable category is better.

The word equivalent needs particular restraint. Failure to find a difference is not automatically proof that two approaches are equivalent. Studies designed to assess equivalence or non-inferiority require a suitable design and pre-specified analytical approach. A small or imprecise study may simply be unable to detect an important difference.

Safety, regulation and evidence are separate questions

Comparative effectiveness, safety and regulatory status should be considered separately. A study that reports a clinical outcome may have limited ability to identify uncommon harms, especially when it is small or has short follow-up. Conversely, a safety concern or regulatory action does not by itself answer whether one intervention is more effective than another in a particular study population.

For PRP, the autologous nature of the preparation is relevant but does not remove procedural considerations. Collection, processing, injection and aftercare all form part of the treatment context. For polynucleotides and extracellular-vesicle-related preparations, the identity and handling of the material are particularly important to interpretation. In every case, the study report should state adverse events, withdrawals and follow-up as clearly as it states any claimed benefit.

Regulatory arrangements are jurisdiction-specific and may change. They can depend on the nature of the material, the route of administration, how a product is supplied and the claims made about it. A general evidence comparison cannot determine whether a particular product, procedure or supply arrangement meets requirements in the UK. Questions about legal status should therefore be checked against current advice from the relevant UK authorities rather than inferred from a research paper or a category label.

Neither an explanation of a possible biological mechanism nor a laboratory finding is a substitute for clinical safety reporting. A sound comparison asks what adverse outcomes were actively collected, for how long participants were followed and whether the intervention in the paper is adequately described. It does not assume safety or effectiveness from the word regenerative.

Limits of this comparison

This reference does not establish that polynucleotides, PRP or an exosome-related preparation will work for a particular person, condition or treatment area. It does not provide diagnosis, individual treatment selection, dosing, injection technique, treatment schedules or aftercare instructions. Those matters require an assessment that considers the person's medical history, the condition being addressed and the specific intervention proposed.

It does not present exosome-related preparations as a single uniform treatment class. The International Society for Extracellular Vesicles' terminology guidance illustrates why preparation characterisation matters. Where a study does not adequately describe the material, a reader should not assume that its findings apply to another preparation with a similar label.

The comparison also does not convert absence of a direct study into evidence that no study exists or that no effect is possible. It means that a specific comparative conclusion should not be drawn without locating and appraising an appropriate study. New evidence can alter an assessment, but it should be examined for intervention definition, study design, indication, outcomes and follow-up before it changes the wording of a claim.

This page is not a directory of providers and does not assess individual practitioners, products or venues. It does not use testimonials, promotional images or uncontrolled claims as comparative evidence. Its purpose is narrower: to provide a consistent threshold for deciding whether a statement actually compares polynucleotides, PRP and exosome-related preparations, rather than placing unrelated evidence side by side.